ABSTRACT
ABSTRACT: Biomarkers such as Hypoxia Inducible Factor 1α (HIF-1α), Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 profile mammary carcinoma tissue and Malignant Tumor Specific Growth Factor (TSGF), Cancer Antigen 153 (CA153) in serum plays a significant role in patient management and treatment and can be used as prognostic factors. Aim of this study was to study the express of ER, PR, HER2 and HIF-1α in tissue and serum CA153 and TSGF levels in judging the treatment effect of mammary carcinoma. We analyzed the express of above biomarkers in 52 cases mammary carcinoma, and serum CA153 and TSGF levels in 43 cases mammary carcinoma before and after neoadjuvant chemotherapy. Our results demonstrated that before and after therapy, the expression of PR and HIF-1α had decreased significantly (P < 0.05). The chemosensitivity of HIF-1α positive expression and TSGF and CA153 positive group were worse than those of HIF-1α nagetive expression and TSGF and CA153 nagetive group (P < 0.05). Profiles for ER and HER2 were not significantly different before and after neoadjuvant chemotherapy.
